NCT01842360View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

May 6, 2013

Primary Completion Date

July 29, 2019

Study Completion Date

August 2, 2023

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
BIOLOGICAL

Placebo

The participants will receive daily dose of placebo during 12 months sublingually.

BIOLOGICAL

MV130

The participants will receive daily dose of MV130 during 12 months sublingually.

Trial Locations (7)

28007

Hospital General Universitario Gregorio Marañón, Madrid

28031

Hospital Universitario Infanta Leonor, Madrid

28040

Hospital Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

28850

Hospital Universitario de Torrejón, Torrejón de Ardoz

08500

Hospital Universitario de Vic, Vic

Sponsors

Lead Sponsor

Inmunotek S.L.
All Listed Sponsors
lead

Inmunotek S.L.

INDUSTRY

NCT01842360 - Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter